Formycon AG is an independent developer of biopharmaceutical biosimilars, focusing on therapies for ophthalmology, immunology, and other chronic diseases. The company manages the full development lifecycle, including technical-pharmaceutical development, clinical trials, and regulatory submissions for markets in the EU, USA, Japan, Canada, and Australia. Formycon utilizes AI-supported technologies to optimize its development efficiency under the FYB4GROWTH strategy. A key partnership with Zydus has resulted in the FDA acceptance of FYB206 for review as a Keytruda biosimilar. The company’s scientific team brings expertise from the development of the world's first biosimilars, covering market analysis, protein analytics, manufacturing process development, and clinical development.

Summarised from the company's own disclosures, fiscal year ended Oct 2026

Industry Biotechnology Homepage formycon.com
Sector Healthcare IR page formycon.com/investoren
Tags
biosimilars, ophthalmology, immunology, chronic diseases, biopharmaceuticals, clinical trials, regulatory affairs, ai-supported development, FYB206, FYB4GROWTH, Keytruda, Zydus
Press page —

Metrics

Valuation  
Market cap € 333.665M
Market cap (USD) $ 368.766M
P/E -13.29
PEG —
P/BV 0.87
P/S 7.50
P/OCF 30.94
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE -15.0%
ROI -16.2%
ROIC -5.7%
Profit margin -145.5%
Growth  
Revenue growing No
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 0
Quality score -56.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017
Revenue 44.476M 69.674M 69.674M 42.497M 36.965M 34.227M 33.157M 42.994M 29.004M
Net profit -64.696M -125.671M -125.671M 35.992M — — — — —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017
Share price 25.5 53.1 53.1 85.4 59 53 31.9 — —
Price performance 12m -0.52 0 -0.38 0.45 0.11 0.66 — — —

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Prompts

Formycon AG (ticker FYB), listed in Germany.

ETFs Holding Formycon AG

ETF Weight in ETF Shares Market value As of
AVDV 0.01% 71,505 $ 1.209M Nov 16, 2026
AVDE 0.00% 3,772 $ 63.799K Nov 16, 2026